What is Scailyte?
Scailyte AG, a spin-off from ETH Zurich, is at the forefront of disease biomarker identification, specializing in oncology and immunology. The company integrates cutting-edge single-cell technologies, comprehensive datasets, and sophisticated machine learning methodologies. Its proprietary ScaiVision platform is designed to associate multimodal single-cell data, including RNA-, TCR-, and BCR-seq, alongside proteomics, with critical clinical endpoints such as disease diagnosis, progression, severity, and treatment response. This AI-driven, single-cell resolution approach enables the identification of ultra-sensitive biomarker signatures, positioning ScaiVision as a powerful tool for developing precise diagnostic and predictive therapy response methods. Scailyte actively collaborates with a global network of clinicians to pinpoint indications with high unmet medical needs and partners with leading pharmaceutical and biotech firms to translate these novel biomarkers into companion diagnostics (CDx) and in-vitro diagnostic (IVD) assays.
How much funding has Scailyte raised?
Scailyte has raised a total of $2.9M across 1 funding round:
Angel/Seed
$2.9M
Angel/Seed (2018): $2.9M with participation from Swisscom Ventures
Key Investors in Scailyte
Swisscom Ventures
Swisscom Ventures is an investment firm that likely focuses on technology and innovation, potentially backing companies with strong scientific foundations and market potential, as indicated by their participation in Scailyte's early-stage funding.
What's next for Scailyte?
With a substantial enterprise-level funding context, Scailyte is poised for significant scaling and further development of its biomarker discovery and diagnostic platforms. The company's strategic focus on translating single-cell data and AI-driven insights into actionable diagnostic tools suggests a trajectory towards expanding its partnerships with global pharmaceutical and biotech entities. Future growth will likely involve enhancing the capabilities of the ScaiVision platform, broadening its application across more disease indications, and accelerating the commercialization of its CDx and IVD assays. Continued investment will be crucial for navigating the complex regulatory landscape and solidifying its market position in precision medicine.
See full Scailyte company page
